Nevro Corp. (NVRO)
NYSE NYSE Primary 
Nevro resumed with an Equal Weight at Wells Fargo
Wells Fargo resumed coverage of Nevro with an Equal Weight rating and $5 price target. Wells believes Nevro is comfortable with consensus implying a return to year over year sales growth in the second half of 2025, though the firm does not see upside to Street estimates, the analyst tells investors in a research note. Easier y/y comps, lessened competitive trialing, AdaptivAI ramp, continued healthy growth in painful diabetic neuropathy, adding new sales territories, and Vyrsa ramping could support 2025 growth, the firm says.
NVRO Stock Declines Despite Positive Study Data of Nevro1 System
Nevro unveils publication of positive data study regarding its Nevro1 SI Joint Fusion System.
Nevro Stock May Gain on the CE Mark Certification for HFX iQ
NVRO's HFX iQ SCS system receives CE Mark Certification in Europe. Nevro expects to begin launching HFX iQ in select European countries from the first quarter of 2025.
Nevro Stock Rises on Q3 Earnings Beat, Revenues Decrease Y/Y
NVRO's third-quarter earnings beat its Zacks Consensus Estimate, while worldwide revenues decline year over year. The company continues to incur losses at the operating level.
Nevro Corp. (NVRO) Q3 2024 Earnings Call Transcript
Nevro Corp. (NYSE:NVRO ) Q3 2024 Earnings Conference Call November 11, 2024 4:30 PM ET Company Participants Angie McCabe - Vice President, Investor Relations & Corporate Communications Kevin Thornal - Chief Executive Officer & President Rod MacLeod - Chief Financial Officer Conference Call Participants Chris Pasquale - Nephron Research Shagun Singh - RBC Capital Markets Robbie Marcus - JPMorgan Matt Taylor - Jefferies Brandon Vazquez - William Blair Bill Plovanic - Canaccord Suraj Kalia - Oppenheimer Richard Newitter - Truist Securities David Rescott - Baird Operator Good afternoon. My name is Krista, and I will be your conference operator today.
Nevro (NVRO) Reports Q3 Loss, Tops Revenue Estimates
Nevro (NVRO) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to loss of $0.65 per share a year ago.
Here's Why you Should Retain Nevro Stock in Your Portfolio Now
Strength in NVRO's Senza Platform and business diversification plans raises optimism about the stock.
NVRO Stock May Gain on the FDA Approval of Its HFX AdaptivAI Platform
Nevro announces the FDA approval and limited market release of HFX iQ with HFX AdaptivAI.
Here's Why You Should Retain Nevro (NVRO) Stock for Now
Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.
Nevro: Not Having My Back
Nevro Corp.'s shares hit fresh lows after revenue guidance reset, reflecting stagnant growth and substantial losses. The company has seen an eventful decade with huge share price fluctuations, but the situation is quite severe right now. Competitive pressures hurt the topline sales, as the loss rate is very substantial, leaving few opportunities to grow out of this situation here.
Nevro's (NVRO) Q2 Earnings Beat Estimates, Revenues Down Y/Y
Nevro's (NVRO) second-quarter earnings beat the Zacks Consensus Estimate while worldwide revenues decline year over over. The company incurs a loss at the operating level.
Nevro Corp. (NVRO) Q2 2024 Earnings Call Transcript
Nevro Corp. (NYSE:NVRO ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Angie McCabe - VP, IR & Corporate Communications Kevin Thornal - Chief Executive Officer & President Rod MacLeod - Chief Financial Officer Conference Call Participants Nathan Treybeck - Wells Fargo Robbie Marcus - JPMorgan Brandon Vazquez - William Blair Anthony Petrone - Mizuho Bill Plovanic - Canaccord David Rescott - Baird Operator Good afternoon. My name is Mark, and I will be your conference operator today.
